This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Pranoprofen is a topical anti-inflammatory agent used for the treatment of non-infectious inflammatory conditions such as blepharitis and conjunctivitis. Pranoprofen ophthalmic solution may also be used post-operatively to manage inflammation.
- Generic Name
- Pranoprofen
- DrugBank Accession Number
- DB13514
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Pranoprofen (DB13514)
- Weight
- Average: 255.2686
Monoisotopic: 255.089543287 - Chemical Formula
- C15H13NO3
- Synonyms
- Pranoprofen
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Pranoprofen. Acemetacin The risk or severity of adverse effects can be increased when Pranoprofen is combined with Acemetacin. Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pranoprofen. Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Pranoprofen. Aminophenazone The risk or severity of adverse effects can be increased when Aminophenazone is combined with Pranoprofen. Amitriptyline The risk or severity of gastrointestinal bleeding can be increased when Amitriptyline is combined with Pranoprofen. Amitriptylinoxide The risk or severity of gastrointestinal bleeding can be increased when Amitriptylinoxide is combined with Pranoprofen. Amoxapine The risk or severity of gastrointestinal bleeding can be increased when Amoxapine is combined with Pranoprofen. Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Pranoprofen. Antrafenine The risk or severity of adverse effects can be increased when Antrafenine is combined with Pranoprofen. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- S01BC09 — Pranoprofen
- Drug Categories
- Acids, Acyclic
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antigout Preparations
- Antirheumatic Agents
- Fatty Acids
- Fatty Acids, Volatile
- Heterocyclic Compounds, Fused-Ring
- Lipids
- Nephrotoxic agents
- Non COX-2 selective NSAIDS
- Ophthalmologicals
- Peripheral Nervous System Agents
- Pyrans
- Sensory Organs
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as chromeno[2,3-b]pyridines. These are aromatic heteropolycyclic compounds containing pyridine linearly fused to the pyran moiety of a benzofuran ring system.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzopyrans
- Sub Class
- 1-benzopyrans
- Direct Parent
- Chromeno[2,3-b]pyridines
- Alternative Parents
- Diarylethers / Pyranopyridines / Pyridines and derivatives / Benzenoids / Heteroaromatic compounds / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds show 4 more
- Substituents
- Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Chromeno[2,3-b]pyridine / Diaryl ether / Ether / Heteroaromatic compound show 11 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 2R7O1ET613
- CAS number
- 52549-17-4
- InChI Key
- TVQZAMVBTVNYLA-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H13NO3/c1-9(15(17)18)10-4-5-13-12(7-10)8-11-3-2-6-16-14(11)19-13/h2-7,9H,8H2,1H3,(H,17,18)
- IUPAC Name
- 2-{5H-chromeno[2,3-b]pyridin-7-yl}propanoic acid
- SMILES
- CC(C(O)=O)C1=CC2=C(OC3=C(C2)C=CC=N3)C=C1
References
- General References
- TITCK Product Information: Oftalar (pranoprofen) ophthalmic drops [Link]
- External Links
- Human Metabolome Database
- HMDB0041996
- ChemSpider
- 4719
- BindingDB
- 50286819
- ChEBI
- 32040
- ChEMBL
- CHEMBL367463
- Wikipedia
- Pranoprofen
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Macular Edema 1 Not Available Completed Treatment Retinal Diseases 1 Not Available Unknown Status Not Available Keratitis, Herpetic 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Ophthalmic 0.00100 g Solution / drops Ophthalmic Solution / drops Ophthalmic 5 ml Solution / drops Ophthalmic 0.1 % - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.03 mg/mL ALOGPS logP 2.54 ALOGPS logP 2.94 Chemaxon logS -2.4 ALOGPS pKa (Strongest Acidic) 3.63 Chemaxon pKa (Strongest Basic) 2.24 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 59.42 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 70.02 m3·mol-1 Chemaxon Polarizability 26.86 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0a4i-1290000000-d70f1e7dd20d79171ae0
Enzymes
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Components:
References
- Notivol R, Martinez M, Bergamini MV: Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Pranoprofen Study Group. Am J Ophthalmol. 1994 May 15;117(5):651-6. doi: 10.1016/s0002-9394(14)70073-x. [Article]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Regulator
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Nomura T, Sakamoto K, Imai T, Otagiri M: Study of interaction of pranoprofen with human serum albumin: binding properties of enantiomers and metabolite. J Pharmacobiodyn. 1992 Oct;15(10):589-96. doi: 10.1248/bpb1978.15.589. [Article]
Drug created at June 23, 2017 20:43 / Updated at May 15, 2021 22:41